![Biohaven Presents New Migraine Data at 64th Annual Scientific Meeting of the American Headache Society, including First of Its Kind Study for Nurtec® ODT (rimegepant), and Complete Phase 3 Data for Zavegepant Biohaven Presents New Migraine Data at 64th Annual Scientific Meeting of the American Headache Society, including First of Its Kind Study for Nurtec® ODT (rimegepant), and Complete Phase 3 Data for Zavegepant](https://mma.prnewswire.com/media/1837779/Pain_relief_zavegepant_301_6_9_22.jpg?p=facebook)
Biohaven Presents New Migraine Data at 64th Annual Scientific Meeting of the American Headache Society, including First of Its Kind Study for Nurtec® ODT (rimegepant), and Complete Phase 3 Data for Zavegepant
![Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial - The Lancet Neurology Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial - The Lancet Neurology](https://www.thelancet.com/cms/attachment/e57cd4de-b88c-4072-be8f-bad7cca4ea2f/gr4_lrg.jpg)
Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial - The Lancet Neurology
![Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial - The Lancet Neurology Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial - The Lancet Neurology](https://www.thelancet.com/cms/attachment/758fba25-445f-4cce-a682-6346499928ba/gr2_lrg.jpg)
Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial - The Lancet Neurology
![Pfizer's zavegepant (ZAVZPRET™) Migraine Nasal Spray Receives FDA Approval | American Headache Society Pfizer's zavegepant (ZAVZPRET™) Migraine Nasal Spray Receives FDA Approval | American Headache Society](https://americanheadachesociety.org/wp-content/uploads/2018/06/GettyImages-497749034-1-e1528150511497_500x350_acf_cropped.jpg)
Pfizer's zavegepant (ZAVZPRET™) Migraine Nasal Spray Receives FDA Approval | American Headache Society
![Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial - The Lancet Neurology Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial - The Lancet Neurology](https://www.thelancet.com/cms/attachment/4e24bb07-29fd-4218-8637-6b6b53e4f9b5/gr1.gif)